Educated Patient® Lung Cancer Summit Basics of Lung Cancer Session: August 14, 2021

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

The Food and Drug Administration approved Augtyro for patients over the age of 12 with NTRK-positive solid tumors.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

The Food and Drug Administration will speed up their review and potential approval of Tagrisso for certain patients with EGFR-mutant lung cancer.

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.